The authors are retracting this Article. The Article comprises three parts: a case-control study; a meta-analysis of case-control studies; and Mendelian randomization (MR) analyses (two datasets; a Japanese dataset and a public genome-wide association study [GWAS]-pooled dataset). In the MR analysis using the public dataset, the authors mistook effect alleles, resulting in incorrect results (Figure 3) and conclusion.
Our updated MR results are as follows: odds ratio (OR)scz/crp 0.87 (95% CI 0.76–1.00, p = 0.046) using rs2794520; 0.83 (95% CI 0.72–0.96, p = 0.014) using rs1183910; 0.85 (95% CI 0.77–0.94, p = 0.0017) across these two single nucleotide polymorphisms (SNPs); and 0.89 (95% CI 0.82–0.97, p = 0.006) using 15 C-reactive protein (CRP)-associated SNPs, which reached genome-wide significance in a meta-analysis of GWAS, respectively. These updated results of the MR analysis using the limited number of SNPs indicate a protective causal association between elevated CRP levels and schizophrenia risk. Therefore, the hypothesis in the conclusion of the Article—that medications which reduce CRP levels can be used in schizophrenia—is not supported.
All authors recognize these miscalculations in the original MR analysis and have agreed to the retraction of this Article.
About this article
Search for Masatoshi Inoshita in:
Search for Shusuke Numata in:
Search for Atsushi Tajima in:
Search for Makoto Kinoshita in:
Search for Hidehiro Umehara in:
Search for Masahito Nakataki in:
Search for Masashi Ikeda in:
Search for Souichiro Maruyama in:
Search for Hidenaga Yamamori in:
Search for Tetsufumi Kanazawa in:
Search for Shinji Shimodera in:
Search for Ryota Hashimoto in:
Search for Issei Imoto in:
Search for Hiroshi Yoneda in:
Search for Nakao Iwata in:
Search for Tetsuro Ohmori in: